Anonymous
Guest
Anonymous
Guest
Just a note to say thank you to all the AAH folks. I've appreciated working here regardless of this Zoetis outcome. Hope you have a great Thanksgiving and wishing you the best on this new journey.
Just a note to say thank you to all the AAH folks. I've appreciated working here regardless of this Zoetis outcome. Hope you have a great Thanksgiving and wishing you the best on this new journey.
Zoetis was poised for new product growth even without the AAH acquisition. Once they have enough product, Apoquel alone will be a monster. They need more reps, which should be good news for many of you.
It's an interesting dynamic.
Billionaire Bill Ackman picked up about a 10% stake in Zoetis two weeks ago. At the same time his Valeant Pharmaceuticals is making a big play for Allergan. Talk was that Zoetis would be a nice acquisition for Valeant as well. Now you read an article like this from the analysts and they throw Bayer's name in the mix, which makes sense as well. So with the unfavoriable numbers commited to the Street, and the Street's reaction, Zoetis will need to do what is best for their shareholders which is to maximize their market capitalization. If that mean Valeant or Bayer coming along to pick them up, it could get real interesting.
What is a little silly is why they were so interested in us to begin with. Our products compliment theirs, but how do you take a business the size of ours ( < $100MM ) and have it generate momentum within a $4.2BN giant? I'm sure Miles is very happy with the $255MM he is getting on this tidy sale, but Zoetis might be up to their ears in other, BIGGER deals within a few weeks. Would seem we would drop to the bottom of their priority list when the numbers end with nine zeros, as opposed to six.
Also, if you are interested in what Zoetis is thinking, take a look at the Pfizer Animal Health board. They are talking about lay-offs more than we are!
Stay Tuned...